US-based Corvida Medical has launched a multi-centre research study to evaluate improvements that its Closed System Transfer Device (CSTD) technology could bring to the safe handling of hazardous drugs.
The study is funded by the National Cancer Institute (NCI) as part of a series of Small Business Innovation Research (SBIR) grants.
The company is currently seeking study participants to join the country's leading cancer centres in a one day evaluation of medical devices used to improve safe handling of hazardous drugs.
More than 5.5 million healthcare workers annually are at risk of exposure to hazardous pharmaceuticals during the preparation and delivery of chemotherapy.
Studies showed exposure to hazardous drugs can cause serious health problems, according to Occupational Safety and Health Administration (OSHA), National Institute of Occupational Safety and Health (NIOSH) and Joint Commission.
NIOSH defined a CSTD as a drug transfer device, which prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapour concentrations outside the system.
Corvida Medical president Kent Smith said: "The grants from the NCI will help us advance Corvida's soon-to-be-launched family of Halo brand CSTD products.
"The NCI SBIR study is a significant effort by the company to get leading cancer institutions in the US to explore applications of Halo and to demonstrate forward movement in safe handling."
Corvida Medical addresses the problems inherent in current CSTDs and develops smarter, simpler solutions to improve safety, productivity and quality for providers and patients.